Clinical Significance of Isolated V1 Arteritis in Renal Transplantation.


Journal

Transplantation proceedings
ISSN: 1873-2623
Titre abrégé: Transplant Proc
Pays: United States
ID NLM: 0243532

Informations de publication

Date de publication:
Jun 2021
Historique:
received: 09 12 2020
accepted: 03 03 2021
pubmed: 18 5 2021
medline: 13 7 2021
entrez: 17 5 2021
Statut: ppublish

Résumé

The presence of intimal arteritis (v) in renal allograft biopsy specimens establishes the presence of acute T-cell mediated rejection (TCMR), Grade IIa-III, according to the Banff classification of rejection. The clinical significance of isolated v1 lesions (v1), characterized by arteritis alone, compared with lesions of arteritis with tubulointerstitial inflammation (i-t-v) has been controversial. We performed a retrospective review of 280 patients undergoing renal transplantation between 2005 and 2015 who received a "for cause" transplant biopsy using the Banff 2013 classification. Patients with TCMR grade IIa (n = 83) were subdivided into groups with isolated v1 arteritis and i-t-v. Pre- and postoperative renal function, graft survival, and overall survival were evaluated in all patients. Donor and recipient demographics were similar between groups. One month following treatment of rejection, patients with v1 disease had superior recovery of glomerular filtration rate vs patients with i-t-v (P < .002). At a median follow-up of 41 months from transplant, death-censored graft survival was 92% vs 79% (P = .04), and overall survival was 98% vs 79% (P < .004) in the isolated v1 and i-t-v groups, respectively. Despite having identical Banff classification of TCMR IIa, our results indicate that graft survival in patients with isolated v1 rejection is superior to those with i-t-v. Following corroboration with data from other centers, modification of the Banff classification scheme should be considered.

Sections du résumé

BACKGROUND BACKGROUND
The presence of intimal arteritis (v) in renal allograft biopsy specimens establishes the presence of acute T-cell mediated rejection (TCMR), Grade IIa-III, according to the Banff classification of rejection. The clinical significance of isolated v1 lesions (v1), characterized by arteritis alone, compared with lesions of arteritis with tubulointerstitial inflammation (i-t-v) has been controversial.
METHODS METHODS
We performed a retrospective review of 280 patients undergoing renal transplantation between 2005 and 2015 who received a "for cause" transplant biopsy using the Banff 2013 classification. Patients with TCMR grade IIa (n = 83) were subdivided into groups with isolated v1 arteritis and i-t-v. Pre- and postoperative renal function, graft survival, and overall survival were evaluated in all patients.
RESULTS RESULTS
Donor and recipient demographics were similar between groups. One month following treatment of rejection, patients with v1 disease had superior recovery of glomerular filtration rate vs patients with i-t-v (P < .002). At a median follow-up of 41 months from transplant, death-censored graft survival was 92% vs 79% (P = .04), and overall survival was 98% vs 79% (P < .004) in the isolated v1 and i-t-v groups, respectively.
CONCLUSION CONCLUSIONS
Despite having identical Banff classification of TCMR IIa, our results indicate that graft survival in patients with isolated v1 rejection is superior to those with i-t-v. Following corroboration with data from other centers, modification of the Banff classification scheme should be considered.

Identifiants

pubmed: 33994184
pii: S0041-1345(21)00220-7
doi: 10.1016/j.transproceed.2021.03.027
pii:
doi:

Types de publication

Evaluation Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1570-1575

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

David Mikhail (D)

Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada; Division of Urology, Department of Surgery, London Health Sciences Center, London, Ontario, Canada.

Ernest Chan (E)

Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada; Division of Urology, Department of Surgery, London Health Sciences Center, London, Ontario, Canada.

Hemant Sharma (H)

Multi-Organ Transplant Program, London Health Sciences Center, London, Ontario, Canada.

Derek Kleinsteuber (D)

Department of Pathology and Laboratory Medicine, London Health Sciences Center, London, Ontario, Canada; Department of Medicine, London Health Sciences Center, London, Ontario, Canada.

James Wei (J)

Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.

Claire Rim (C)

Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.

Marina Henein (M)

Department of Pathology and Laboratory Medicine, London Health Sciences Center, London, Ontario, Canada; Department of Medicine, London Health Sciences Center, London, Ontario, Canada.

Alp Sener (A)

Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada; Division of Urology, Department of Surgery, London Health Sciences Center, London, Ontario, Canada; Multi-Organ Transplant Program, London Health Sciences Center, London, Ontario, Canada.

Anthony M Jevnikar (AM)

Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada; Multi-Organ Transplant Program, London Health Sciences Center, London, Ontario, Canada.

Manal Gabril (M)

Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada; Multi-Organ Transplant Program, London Health Sciences Center, London, Ontario, Canada; Department of Pathology and Laboratory Medicine, London Health Sciences Center, London, Ontario, Canada; Department of Medicine, London Health Sciences Center, London, Ontario, Canada.

Madeleine Moussa (M)

Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada; Multi-Organ Transplant Program, London Health Sciences Center, London, Ontario, Canada; Department of Pathology and Laboratory Medicine, London Health Sciences Center, London, Ontario, Canada; Department of Medicine, London Health Sciences Center, London, Ontario, Canada.

Patrick P Luke (PP)

Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada; Division of Urology, Department of Surgery, London Health Sciences Center, London, Ontario, Canada; Multi-Organ Transplant Program, London Health Sciences Center, London, Ontario, Canada; Department of Pathology and Laboratory Medicine, London Health Sciences Center, London, Ontario, Canada; Department of Medicine, London Health Sciences Center, London, Ontario, Canada. Electronic address: patrick.luke@lhsc.on.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH